The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment

Rahul A. Parikh, Peng Wang, Jan H. Beumer, Edward Chu, Leonard J. Appleman

Research output: Contribution to journalReview articlepeer-review

49 Scopus citations

Abstract

MET is located on chromosome 7q31 and is a proto-oncogene that encodes for hepa-tocyte growth factor (HGF) receptor, a member of the receptor tyrosine kinase (RTK) family. HGF, also known as scatter factor (SF), is the only known ligand for MET. MET is a master regulator of cell growth and division (mitogenesis), mobility (motogenesis), and differentiation (morphogenesis); it plays an important role in normal development and tissue regeneration. The HGF-MET axis is frequently dysregulated in cancer by MET gene amplification, translocation, and mutation, or by MET or HGF protein overexpression. MET dysregulation is associated with an increased propensity for metastatic disease and poor overall prognosis across multiple tumor types. Targeting the dysregulated HGF-MET pathway is an area of active research; a number of monoclonal antibodies to HGF and MET, as well as small molecule inhibitors of MET, are under development. This review summarizes the key biological features of the HGF-MET axis, its dysregulation in cancer, and the therapeutic agents targeting the HGF-MET axis, which are in development.

Original languageEnglish (US)
Pages (from-to)969-983
Number of pages15
JournalOncoTargets and Therapy
Volume7
DOIs
StatePublished - Jun 11 2014
Externally publishedYes

Keywords

  • Cancer
  • HGF inhibitor
  • MET inhibitor

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment'. Together they form a unique fingerprint.

Cite this